AQUILON PHARMACEUTICALS
0540.870.218 · rovalta.com · 24/09/2026
ACTIVE
AQUILON PHARMACEUTICALS
Financial year 2025 · Closed on 31/12/2025
Net result-444,1 k €+51,4 %over 1 year
Gross margin1,3 M €+26,8 %over 1 year
Equity4,3 M €+228,2 %over 1 year
Workforce8,7 ETP-7,4 %over 1 year
Overview
Identity
Source · BCE/KBOAQUILON PHARMACEUTICALS is a Public limited company incorporated in 2013. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Seraing. It employs on average 8,7 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0540.870.218
- Incorporation
- 16/10/2013
- Legal form
- Public limited company
- Registered office
- Rue du Bois St-Jean 15/1
4102 Seraing · WallonieSee on map - Contributed capital
- 5 486 277,23 €
- Latest accounts
- 31/12/2025
- Average workforce
- 8,7 ETP
Activities (NACE)
Joint committees (2)
- 100
- 207
Contacts
2 public details availableLog in to view
Signals
Solid equityPositive cashflowPositive EBITDAHealthy social debts
Financials
Source · NBB, 15 filingsTrend over 11 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 1,3 M € | +26.8% | 991,8 k € | +8.1% | 917,2 k € | +103% | 451,1 k € | +190% | 155,3 k € |
| EBITDA | 531,9 k € | +914% | -65,3 k € | +44.1% | -116,8 k € | +54.7% | -258,1 k € | +39.0% | -423 k € |
| Operating result | -102,1 k € | +81.7% | -558,6 k € | +18.5% | -685,8 k € | -13.7% | -603,1 k € | -8.0% | -558,6 k € |
| Net result | -444,1 k € | +51.4% | -913,7 k € | +2.5% | -936,7 k € | -22.8% | -762,5 k € | -21.2% | -629,1 k € |
| Balance sheet | |||||||||
| Equity | 4,3 M € | +228% | 1,3 M € | -30.4% | 1,9 M € | +145% | 760,8 k € | -50.1% | 1,5 M € |
| Total assets | 11,1 M € | +7.8% | 10,3 M € | +5.3% | 9,8 M € | +25.2% | 7,8 M € | +24.1% | 6,3 M € |
| Cash | 389 k € | +86.7% | 208,4 k € | -61.1% | 535,3 k € | -11.3% | 603,1 k € | -41.2% | 1 M € |
| Debts | 6,9 M € | -23.7% | 9 M € | +13.6% | 7,9 M € | +12.1% | 7,1 M € | +47.7% | 4,8 M € |
| Other | |||||||||
| Workforce | 8,7 ETP | -7.4% | 9,4 ETP | +2.2% | 9,2 ETP | +12.2% | 8,2 ETP | +17.1% | 7,0 ETP |
Valuation
Indicative valuation
As an indication, this company is worth
between 0 € and 100 k€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20257 active · 33 ended
Active mandates
Charles NELLES
ActiveDidier CATALDO
ActiveFrank PIETERS
ActiveActive
Active
Hassan BENAMEUR
ActiveMoshe MANOR
ActiveEnded mandates
Hassan BENAMEUR
EndedMichaël MELLINK
EndedMichaël MELLINK
EndedMoshe MANOR
EndedOther companies at this address
Rue du Bois St-Jean 15/1 4102 Seraing| Company | CBE no. |
|---|---|
ALIZES PHARMA● Active | 1040.385.871 |
ALPHACOMSOLUTION● Active | 0767.826.066 |
AQUITEC PHARMA● Active | 1040.385.970 |
ARTESIA ENVIRONNEMENT● Active | 0688.592.706 |
| 0820.385.022 | |
SYNGULON● Bankrupt | 0521.816.349 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 22/07/2026 | 29/07/2025 | 07/10/2024 | 10/07/2023 | 02/08/2022 | 26/08/2021 |
| General meeting | 06/07/2026 | 02/07/2025 | 16/07/2024 | 29/06/2023 | 13/07/2022 | 07/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 15 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 06/07/2026 | 22/07/2026 | French | |
| Abridged model | 31/12/2024 | 02/07/2025 | 29/07/2025 | French | |
| Abridged modelCorrection | 31/12/2023 | 16/07/2024 | 07/10/2024 | French | |
| Abridged model | 31/12/2023 | 16/07/2024 | 25/07/2024 | French | |
| Abridged model | 31/12/2022 | 29/06/2023 | 10/07/2023 | French | |
| Abridged model | 31/12/2021 | 13/07/2022 | 02/08/2022 | French | |
| Abridged model | 31/12/2020 | 07/06/2021 | 26/08/2021 | French | |
| Abridged model | 31/12/2019 | 25/06/2020 | 16/07/2020 | French | |
| Abridged modelCorrection | 31/12/2018 | 25/06/2019 | 19/07/2019 | French | |
| Abridged model | 31/12/2018 | 31/05/2019 | 24/06/2019 | French | |
| Abridged modelCorrection | 31/12/2017 | 06/07/2018 | 27/08/2018 | French | |
| Abridged model | 31/12/2017 | 06/07/2018 | 16/07/2018 | French | |
| Abridged model | 31/12/2016 | 30/06/2017 | 12/07/2017 | French | |
| Abridged model | 31/12/2015 | 30/04/2016 | 18/07/2016 | French | |
| Abridged model | 31/12/2014 | 30/06/2015 | 31/08/2015 | French |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 0 € and 100 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20257 active · 33 ended
Active mandates
Charles NELLES
ActiveDidier CATALDO
ActiveFrank PIETERS
ActiveActive
Active
Hassan BENAMEUR
ActiveMoshe MANOR
ActiveEnded mandates
Hassan BENAMEUR
EndedMichaël MELLINK
EndedMichaël MELLINK
EndedMoshe MANOR
EndedOwnership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Capital / shares10/08/2026STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Mandates16/09/2025DEMISSIONS, NOMINATIONS
- Capital / shares04/07/2025STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Registered office22/05/2025SIEGE SOCIAL - CAPITAL, ACTIONS - STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Mandates16/04/2025DEMISSIONS, NOMINATIONS
- Capital / shares20/03/2025CAPITAL, ACTIONS
- Capital / shares23/12/2024STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Capital / shares14/11/2023CAPITAL, ACTIONS
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-444,1 k €↑
- 2024Annual accounts 2024-913,7 k €↑
- 2023Annual accounts 2023-936,7 k €↓
- 2022Annual accounts 2022-762,5 k €↓
- 2021Annual accounts 2021-629,1 k €↓
- 2019Annual accounts 2019-325 k €↓
- 2018Annual accounts 2018-257,5 k €↓
- 2017Annual accounts 2017-185,8 k €↓
- 2016Annual accounts 201626,4 k €↑
- 2015Annual accounts 2015-19,3 k €↓
- 2014Annual accounts 2014-12,4 k €
- 16/10/2013IncorporationPublic limited company